Peptide injection technique: a technical reference

The peptide that ends up in plasma is not the peptide that left the vial. Between the sealed lyophilized cake and the receptor it eventually engages sits a sequence of operational decisions — route of administration, needle gauge, injection depth, site selection, syringe calibration, post-injection care — each of which moves the molecule's pharmacokinetic and adverse-event profile measurably. The clearest single piece of evidence is the FDA's July 2024 alert on compounded injectable semaglutide, in which patient-reported overdoses of five to twenty times the intended dose traced almost entirely to syringe-unit-versus-milligram conversion errors rather than to anything that happened inside a manufacturing facility (FDA alert on dosing errors with compounded injectable semaglutide, July 29, 2024). The administration layer is where peptide pharmacology meets the kitchen counter, and the kitchen counter is where most of the avoidable adverse events occur.

This reference walks the technique layer: route-of-administration trade-offs, needle gauge and syringe-volume math, reconstitution arithmetic and conversion errors, site rotation and the lipohypertrophy biology behind it, pre- and post-injection technique, special cases (long-acting depots, pulsatile peptides, FDA-approved auto-injectors), the common-error catalog, and the special-populations layer. It sits alongside the peptide storage and stability technical reference, which covers what happens between manufacture and reconstitution, and the peptide pharmacokinetics matrix, which covers what the molecule does once in circulation. The companion critic on injection technique doesn't matter addresses the over-correction that route is irrelevant; this dossier is the positive guidance the critic rebuts against. The frame is educational. No therapeutic claims are made. Vendor channels are not named.

1. Why technique matters

Injection technique modulates four operational variables simultaneously: bioavailability (what fraction of the dose reaches systemic circulation), onset and peak timing (when plasma Cmax occurs and how flat or sharp the curve is), adverse-event spectrum (injection-site reactions, lipodystrophy, dose-conversion overdoses), and adherence (whether the user actually completes the protocol).

For the FDA-approved peptides, the package insert defines administration technique with regulator-validated specificity. Wegovy semaglutide is labeled for subcutaneous injection in the abdomen, thigh, or upper arm once weekly, with the three sites established as bioequivalent in formal pharmacokinetic studies (WEGOVY prescribing information, 2025). Mounjaro and Zepbound carry analogous subq labeling. Egrifta WR tesamorelin specifies subcutaneous abdominal injection following reconstitution with bacteriostatic water (2025 PI). Vyleesi bremelanotide is supplied as a single-dose pre-filled autoinjector for subq thigh or abdomen administration (Vyleesi PI, 2019). For these molecules, the labeled route was studied in the pivotal trials, and the approval rests on data generated using that route at the labeled dose.

For the gray-market peptides — BPC-157, TB-500, GHK-Cu, KPV, Ipamorelin, CJC-1295, Selank, Semax, Epitalon, and the rest of the research-channel corpus — there is no package insert. Practitioner-protocol conventions fill the gap. Those conventions are anchored variably: in the published rodent or small-cohort literature (the Russian-language intranasal Semax/Selank literature is the cleanest case), in compounding-pharmacy practitioner network consensus, or in community forum patterns that pre-date the published evidence base. The "convention" layer is real information but carries less evidentiary weight than the labeling layer. The critic page on injection technique doesn't matter walks the route-by-route case for where conventions are pharmacologically load-bearing (Semax, Selank, Tesamorelin, PT-141, MK-677) and where they are more flexible (some BPC-157 indications, GHK-Cu route choice between subq and topical).

2. Route-of-administration overview

Five routes dominate the peptide field. Each has a characteristic pharmacokinetic signature, a characteristic adverse-event profile, and a characteristic set of molecules it suits.

Subcutaneous (subq)

The dominant route for peptide self-administration. The subcutaneous depot is the layer of adipose and connective tissue between the dermis and the underlying skeletal muscle — typically 5 to 25 mm thick depending on body site, sex, and adiposity. Peptides injected into this depot absorb slowly into systemic circulation through dermal capillaries and lymphatic drainage, producing a flatter and lower plasma curve than intravenous or intramuscular routes. Time to peak plasma concentration (Tmax) is typically 15 to 60 minutes for unmodified short peptides and one to seven days for fatty-acid-acylated long-acting depots; the pharmacokinetics matrix catalogs the per-molecule numbers.

Labeled subq sites for the FDA-approved peptide class are abdomen, thigh, and the posterior upper arm. Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, and Victoza all specify these three sites with bioequivalence demonstrated across them; Egrifta WR specifies abdominal subq for tesamorelin. The posterior flank is used in some practitioner-protocol literature as a fourth site for daily-dosing peptides where the standard three are exhausted by the rotation calendar. For most gray-market peptides, the abdomen-thigh-arm rotation translates directly, with abdomen as the practitioner-default for fast-onset peptides because subcutaneous absorption from abdominal fat is more reproducible across days and meals than from thigh or arm.

Intramuscular (IM)

Faster onset than subq with a higher peak plasma concentration and a sharper curve. The IM depot — skeletal muscle — has substantially higher blood flow than subcutaneous adipose, and the molecule clears into systemic circulation through skeletal-muscle capillaries on a timescale of minutes rather than tens of minutes. The standard adult IM sites are deltoid (up to 1 mL), vastus lateralis on the lateral thigh, and the ventrogluteal site (3 to 5 mL, lower risk of sciatic-nerve impingement than the older dorsogluteal site).

The peptide field uses IM sparingly. Some practitioner protocols for BPC-157 and TB-500 use IM dosing into muscle adjacent to the injury site; the published evidence supporting that route is rodent rather than human (Wang et al., Front Pharmacol 2022, 13:1026182 for BPC-157 PK). Cerebrolysin is administered by IM or slow IV across the labeled 10-to-21-day course. Hexarelin Phase 1 work used both IV and IM dosing (Imbimbo et al., Eur J Clin Pharmacol 1994, 46:421–425). The general pattern is that IM is the route reached for when subq is not adequate — faster onset, larger volume, or older products developed before subq self-administration was the norm. The pain burden is higher than subq; IM needles are typically 23 to 25 gauge at 1 to 1.5 inches.

Intranasal

The route of choice for centrally acting short peptides that need to bypass systemic circulation. Intranasal administration delivers molecule onto the nasal mucosa, from which a fraction absorbs systemically via mucosal capillaries and a separate fraction enters the central nervous system directly via the olfactory and trigeminal nerve pathways — bypassing the blood-brain barrier through anatomical proximity.

The peptide field uses intranasal for Selank and Semax, where the route is the Russian-clinical convention and is supported by direct evidence that intranasal produces a different effect spectrum than systemic (Manchenko et al. 2010 Semax route-dissociation paper; Vasileva et al. 2020 across Selank/Semax/Noopept). Oxytocin research has used intranasal extensively, though the central-versus-peripheral pharmacokinetic question remains debated. PT-141 was developed initially as intranasal before development pivoted to subq for Vyleesi, in part because intranasal PT-141 produced transient blood-pressure elevations at efficacy doses. DSIP and VIP have been administered intranasally in practitioner-protocol contexts.

The dose-accuracy problem for intranasal is real. Spray volume, head position, breath coordination, and the variable surface area of absorptive nasal mucosa all affect deposited dose. Practitioner technique conventions (head tilted slightly back, gentle inhalation rather than forceful sniff, one nostril at a time) emerge from this problem rather than from molecular pharmacology per se.

Oral

The route most peptides cannot use. GI proteolytic enzymes — pepsin in the stomach, trypsin and chymotrypsin and elastase in the small intestine, brush-border peptidases on the enterocyte surface — degrade most peptide bonds before absorption. Oral bioavailability for unmodified peptides is typically below 1% and often closer to zero.

The exceptions are instructive. Rybelsus oral semaglutide — the only FDA-approved oral GLP-1 receptor agonist — achieves approximately 0.4 to 1% bioavailability through co-formulation with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC), which transiently increases gastric epithelial permeability and locally raises pH to protect the molecule from pepsin (Buckley et al., Sci Transl Med 2018, 10:eaar7047). The picomolar receptor affinity combined with the multi-day half-life makes the low bioavailability sufficient for daily oral dosing at substantially higher doses (3 to 14 mg) than the weekly subq presentation (0.25 to 2.4 mg). KPV absorbs orally through PepT1-transporter-mediated uptake, which recognizes the tripeptide as a di- or tripeptide nutrient and translocates it across the small-intestinal epithelium (Dalmasso et al. 2008). MK-677 is a non-peptide ghrelin-receptor agonist designed for oral bioavailability from the outset — the spiropiperidine structure resists the proteolytic gauntlet that destroys peptide-class molecules. Trofinetide (Daybue, FDA-approved March 2023 for Rett syndrome) is administered as a 200 mg/mL oral solution twice daily (Acadia Pharmaceuticals, Daybue prescribing information).

The general pattern: oral peptide delivery requires either an engineered absorption enhancer (SNAC-class), a native transport mechanism the molecule can hijack (PepT1 for di- and tripeptides), or a structural modification that defeats proteolysis. For most peptides in the corpus, the oral route is closed.

Topical

Skin and ocular-surface absorption pathways. Used clinically for GHK-Cu in cosmetic skin applications at 0.05 to 2% concentrations, acting locally on dermal fibroblasts rather than through systemic exposure. Thymosin β4 ophthalmic preparations (RGN-259) have been studied for dry-eye and corneal-healing indications (Sosne 2015 Phase 2 Cornea trial). Some BPC-157 topical preparations exist in practitioner-channel use, though the published evidence base is rodent. SS-31 / elamipretide was evaluated in topical ophthalmic formulations for dry age-related macular degeneration before the program shifted focus to subq systemic dosing for Barth syndrome (Ehlers 2024 ReCLAIM-2 dry AMD trial). The topical route is the only one where systemic exposure is the impurity rather than the goal — the indication is local, and the formulation question is how to keep the molecule in the target tissue rather than push it past the absorption barrier.

3. Needle gauge math

Three numbers describe a syringe-and-needle assembly: barrel volume, graduation system, and needle gauge and length. For peptide self-administration, all three matter and all three are common error sources.

Syringe volume conventions. Insulin syringes are specified in three sizes: U-100 (1 mL, marked in 100 "units"), U-50 (0.5 mL, marked in 50 units), and U-30 (0.3 mL, marked in 30 units). The "U-100" designation derives from insulin's labeled concentration (100 international units per mL); markings are calibrated to read insulin doses directly. All three syringes have the same one-graduation-per-0.01-mL resolution, but the smaller-volume syringes (U-50, U-30) carry that resolution across a longer physical distance per unit, which makes small-dose precision easier. Practitioner convention uses U-30 or U-50 for sub-0.3-mL peptide doses.

The conversion math. A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a 2.5 mg/mL solution. A 250 microgram dose is therefore 250 / 2500 = 0.1 mL, which is 10 units on a U-100 syringe. The same dose in a more dilute reconstitution — 3 mL of BAC water for the same vial, yielding 1.667 mg/mL — would be 0.15 mL or 15 units. The conversion is mechanical, but the mechanics break down whenever any of the three inputs (vial mass, reconstitution volume, target dose) is read wrong.

The misreading. The most-reported error in compounded-peptide dosing is the unit-versus-milligram confusion: a patient reading "10 units" as "10 milligrams" — or as "10 mL" rather than 0.1 mL — delivers a dose off by a factor of 10 to 100. The FDA's July 2024 alert on compounded injectable semaglutide reported adverse-event submissions in which patients self-administered five to twenty times the intended dose, with adverse events ranging from nausea and vomiting to acute pancreatitis, gallstones, and hospitalizations. The errors traced predominantly to dose-conversion mistakes — patients new to self-injection unfamiliar with the relationship between the prescribed milligram dose, the reconstituted-vial concentration, and the syringe-volume graduations.

Needle gauge and length. Subcutaneous injections use short, thin needles — typically 30G or 31G at 5/16" or 1/2" length for adults; the pen needles on the FDA-approved incretin auto-injectors are typically 32G at 4 mm. The FITTER (Forum for Injection Technique and Therapy: Expert Recommendations) 2016 consensus (Frid et al., Mayo Clin Proc 2016, 91:1231–1255) recommends 4 mm pen needles inserted at 90 degrees for all adults regardless of BMI, sex, age, or ethnicity, on the basis that 4 mm reliably reaches the subcutaneous layer without entering muscle. Needles longer than 8 mm have no medical rationale in adult subq administration; longer needles increase the risk of inadvertent IM injection, particularly in lean individuals or at the thigh and arm sites. Intramuscular needles are 23G to 25G at 1" to 1.5" length to reach skeletal muscle beneath the subcutaneous layer.

4. Reconstitution mathematics

Most research-channel peptides ship as lyophilized powder requiring reconstitution. Diluent choice and volume together determine concentration, which determines volume per dose. The peptide storage and stability technical reference covers the stability chemistry; the technique-side point is that the reconstitution-volume choice is a dose-precision decision.

The trade-off. A 5 mg vial in 1 mL of bacteriostatic water yields 5 mg/mL; a 250 microgram dose is 0.05 mL — 5 units on a U-100 syringe, a small volume requiring careful drawing. The same vial in 3 mL yields 1.667 mg/mL; the same dose becomes 0.15 mL or 15 units, with more graduations per unit dose and a corresponding gain in precision. Dilute reconstitution makes the math more forgiving; concentrated reconstitution conserves diluent and produces smaller injection volumes. FDA-approved auto-injector products eliminate the choice entirely by shipping pre-mixed at validated concentrations.

The diluent. Bacteriostatic water for injection (0.9% benzyl alcohol) is the practitioner-default for multi-dose peptide vials, supporting a 28-day in-use window per the Pfizer-Hospira bacteriostatic water labeling. Sterile water for injection (no preservative) is appropriate for single-dose preparations where the full reconstituted volume is administered immediately. Some FDA-approved compounded preparations use sodium acetate buffer or 0.9% sodium chloride for specific stability profiles. The benzyl alcohol in BAC water is contraindicated in neonatal preparations — the "gasping syndrome" toxicity in newborns receiving benzyl-alcohol-preserved IV fluids (Gershanik et al., NEJM 1982, 307:1384–1388) — but the contraindication does not apply to adult research-peptide use.

The illustrative example. A user with a 10 mg Ipamorelin vial reconstituting with 2 mL BAC water has a 5 mg/mL solution; a 300 microgram dose is 6 units on a U-100 syringe. If the user is given a 5 mg vial of the same molecule and reconstitutes with the same 2 mL, concentration is 2.5 mg/mL and the same 300 microgram dose is now 12 units. Same prescribed dose, same syringe, different syringe reading — and the user who carries forward the previous unit count without re-doing the math under-doses by half. The structural failure mode applies across every multi-vial protocol where vial concentration changes between batches or molecules.

5. Injection site rotation

Repeated injection at the same anatomical site produces lipohypertrophy — localized accumulation of subcutaneous fat in response to chronic mechanical and pharmacological insult. Lipohypertrophy slows and makes more variable the absorption of subsequent injections at the affected site, produces palpable subcutaneous nodules, and in extreme cases produces visible cosmetic disfigurement. The phenomenon was first characterized at scale in the insulin-injecting diabetic population, where the relationship between needle reuse, inadequate site rotation, and lipohypertrophy is one of the most reproducibly documented complications in chronic injectable therapy. The countervailing change — lipoatrophy, localized loss of subcutaneous fat — was more common with older animal-source insulin formulations and is rare with modern recombinant insulins; semaglutide and tirzepatide users have reported occasional lipoatrophy-pattern changes at high-frequency chronic sites, though the published evidence is case-report-level.

The rotation recommendation. The FITTER 2016 consensus recommends spacing successive injections by at least 1 cm (the width of an adult finger) within an injection zone and rotating across the four canonical sites (right abdomen quadrant, left abdomen quadrant, right thigh, left thigh — with upper arm and posterior flank as supplementary sites) so that any single site is not used more than once per week. The one-rotation-per-week schedule is the consensus floor; some practitioner-protocol literature suggests 14 days between repeat injections at the same site for chronic-dosing peptides.

Translation across peptide classes. For weekly-dosing FDA-approved peptides (Wegovy, Ozempic, Mounjaro, Zepbound), the rotation calendar is mechanical: each weekly injection goes to a different one of the labeled three sites. For daily-dosing peptides — Selank or Semax intranasal, Sermorelin or Ipamorelin nightly subq, the GH-secretagogue stack protocols — the calendar is denser and lipohypertrophy risk correspondingly higher. The standard practitioner approach for daily peptides is to divide each canonical site into multiple injection points spaced 1 to 2 cm apart and advance through them in a predictable pattern (clockwise around the umbilicus on the abdomen, longitudinally along the thigh) so any single point sees an injection only every 7 to 14 days. For pulsatile-dosing peptides (gonadorelin via pump for fertility-restoration protocols), the calendar becomes the limiting design constraint, and infusion-pump products that distribute dosing over a chronic catheter site rather than discrete injection points emerge in part to manage the site-rotation burden.

Site documentation. Practitioner-protocol literature recommends written or app-based tracking of which sites have been used on which dates, both to support the rotation calendar and to catch slow-onset signs of lipohypertrophy before they alter absorption.

6. Pre-injection technique

Sterile preparation is the load-bearing element. The skin surface carries commensal bacterial flora (typically Staphylococcus epidermidis, occasionally S. aureus); the rubber stopper of the multi-dose vial accumulates contamination from the room environment and from each prior needle penetration; the syringe and needle pass through both surfaces. Each transition point is a potential contamination route.

The standard sequence: hand wash with soap and water (or 60%+ alcohol-based sanitizer where soap is unavailable); alcohol-swab the vial stopper with a fresh 70% isopropyl alcohol pad and air-dry; alcohol-swab the injection site and air-dry. The drying step matters — wet alcohol is not yet doing antimicrobial work, and injecting through a wet site introduces alcohol into the subcutaneous tissue alongside the peptide. The FITTER consensus and the broader injection-technique literature treat 30-second air-drying as the floor.

Aspiration versus non-aspiration. Aspiration — pulling back on the plunger after needle insertion to check for blood return — is the historical convention for IM injections. For subcutaneous injection of small volumes (under 1 mL), aspiration is not required and is not recommended by current consensus. The subcutaneous tissue is not vascularly rich enough to make intravascular injection of a subq bolus a meaningful risk, and the brief delay aspiration introduces increases discomfort without improving safety. The ADA-aligned insulin-administration guidance and the FITTER 2016 consensus both treat aspiration as non-required for subq insulin and incretin administration. For IM injection, aspiration remains the conservative convention in some clinical contexts though even there the evidence base is debated.

Pinch versus flat insertion. A pinch-up of skin and subcutaneous tissue lifts the subq layer away from underlying muscle, reducing inadvertent IM injection risk in lean subjects or at thin-subq sites (deltoid, mid-thigh, posterior flank). Flat insertion at 90 degrees is acceptable at deeper-subq sites (abdomen in average-BMI or higher-BMI subjects). The FITTER consensus recommends 4 mm pen needles at 90 degrees without pinch for most adults; pinch is reserved for lean subjects, deltoid, or any site where subq depth is suspected to be less than needle length. Longer needles (6 to 8 mm) require pinch more consistently.

Insertion speed and dwell time. Single-stroke insertion at 90 degrees (or 45 with pinch for longer needles), steady injection over 2 to 5 seconds for typical subq volumes under 0.5 mL, and a 5-to-10-second hold after the plunger reaches the end to allow the bolus to disperse before withdrawal. Quick withdrawal increases the risk of bolus reflux out the needle track.

7. Post-injection care

Gentle pressure with a sterile gauze pad or alcohol swab for approximately 30 seconds after needle withdrawal closes the puncture track and absorbs any small surface bleeding. Vigorous massage at the injection site is not standard practice — massage can affect local absorption kinetics by accelerating distribution out of the subcutaneous depot, and for long-acting depot peptides (semaglutide, tirzepatide, CJC-1295-DAC) the slow absorption profile is part of the labeled pharmacology rather than an obstacle to be massaged away.

Injection-site reactions in the first 24 to 48 hours — localized erythema, mild swelling, occasional bruising, transient itch — are reported across the peptide class and are typically self-limited. The FDA labels for the major incretin pens list injection-site reactions as common adverse events at low single-digit percentages, with most reactions Grade 1 (mild) and not requiring intervention. Persistent or expanding reactions, signs of infection (warmth, purulent discharge, fever), or anaphylactoid features (urticaria, dyspnea, hypotension) are not the expected post-injection course and warrant clinical evaluation. A site that consistently produces injection-site reactions across multiple dosing events identifies either a localized hypersensitivity, an early lipohypertrophy change, or a sterile-technique gap.

8. Special cases

Long-acting depot peptides

The fatty-acid-acylated GLP-1 / GIP / glucagon multi-agonists (semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide) and the albumin-binding CJC-1295-DAC share a structural property: the fatty-acid handle produces non-covalent or covalent binding to plasma albumin in vivo, slowing renal clearance and extending half-life from hours to days or weeks. For these molecules, subcutaneous absorption from the injection site is one step in a profile dominated downstream by slow albumin dissociation. Subq site choice has measurably less impact on plasma curves than for short-acting molecules — the pharmacokinetic studies underlying the Wegovy and Mounjaro labels demonstrated bioequivalence across abdomen, thigh, and upper-arm sites without dose adjustment. Somapacitan and lonapegsomatropin are the long-acting growth-hormone analogs in the same structural class — albumin-binding or PEGylated to support once-weekly subq dosing for growth-hormone deficiency, with administration technique mirroring the incretin class.

Short-acting peptides

Sermorelin (~15 minute plasma half-life), the unmodified GHRH(1-29) class, and the ghrelin-mimetic GHSR-1a agonists (Hexarelin, GHRP-2, GHRP-6, Ipamorelin ~2 hour half-life) produce a sharp acute GH pulse that resolves within 2 to 4 hours. For short-acting peptides, subq site choice can measurably affect onset timing — abdominal subq absorption is faster and more consistent than thigh or arm, in part because of higher abdominal blood flow and more uniform subq thickness. Practitioner convention for the GH-secretagogue stack is abdominal subq at consistent pre-sleep timing to approximate the endogenous nocturnal GH pulse.

Pulsatile dosing

Some peptide classes require multiple daily doses by design. Sermorelin is dosed nightly. Selank and Semax are dosed 1 to 3 times daily by intranasal route. Gonadorelin in the fertility-restoration context requires pulsatile pump infusion every 90 to 120 minutes — the most extreme pulsatile requirement in the field, driven by the pulsatile-versus-tonic nature of native GnRH receptor signaling (Belchetz et al., Science 1978, 202:631–633). The administration burden scales with frequency: site rotation becomes denser, repeated needle sticks accumulate, and adherence rates decline. The withdrawal of the Lutrepulse and Factrel branded gonadorelin products from the U.S. market was driven in part by the pulsatile-pump requirement.

Reconstituted versus pre-filled

The FDA-approved auto-injectors (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Victoza, Vyleesi) eliminate reconstitution math entirely. The product ships pre-mixed at validated concentrations; the user's responsibility is reduced to site selection, technique, and storage. Compounded-injectable products and research-channel lyophilized vials require user reconstitution; the FDA's July 2024 alert made the structural argument that the pre-filled-pen format is engineered specifically against the dose-conversion error mode that the multi-dose-vial format produces at scale. The pen is not a chemistry-and-controls argument — the same molecule is in both — but a human-factors argument: the format that does not require arithmetic on a syringe barrel does not produce the arithmetic-error class of adverse event.

9. Common errors

The administration-side adverse-event literature for self-injected peptides clusters into a predictable error catalog.

Unit-versus-milligram misreading. The headline error of the compounded-semaglutide cluster. A user reading "10 units" on the syringe as "10 milligrams" delivers a dose off by orders of magnitude depending on the reconstitution concentration. The FDA alert reported five-to-twentyfold overdoses with adverse events including acute pancreatitis and hospitalizations. Mitigation: re-do the conversion math for every new vial, every new concentration, and every new dose; cross-check against the prescribing literature; for compounded products, request explicit per-vial volume-per-dose calculations from the prescribing source rather than translating milligram doses to syringe units independently.

Air bubble paranoia. A small air bubble at the top of a subq insulin syringe is not a clinically meaningful safety concern. The intravenous air-embolism risk that motivates the careful air-purging of IV lines is not operative for subcutaneous injection — subq air absorbs harmlessly over hours through the local capillary network. Excessive concern with air-bubble elimination can produce loss of intended dose during draw-up correction (the user re-draws to eliminate a bubble and ends up with less solution than intended) without any safety improvement. The relevant attention is to the volume reading on the syringe barrel, not to micro-bubbles in the headspace.

Insufficient diluent. Reconstituting a 5 mg vial with 0.5 mL of BAC water produces a 10 mg/mL solution where a 250 microgram dose is 0.025 mL — 2.5 units on a U-100 syringe, with very fine graduations per unit dose and corresponding loss of measurement precision. Practitioner-protocol convention is to use enough diluent to make typical doses fall in the 0.05 to 0.2 mL range (5 to 20 units on a U-100), where the syringe graduations support reproducible dosing.

Cross-contamination across vials. Drawing from one peptide vial, partially injecting, then drawing from a second peptide vial through the same syringe introduces one peptide into the other's container. The contaminated vial then carries cross-degradation chemistry, and any subsequent draws from either vial are no longer clean. The mitigation is one syringe per vial: separate syringes for each peptide in a multi-peptide protocol, with the dose-combination math done on the calculator rather than via vial cross-contamination.

Same-site repeat injection. Chronic dosing into a single anatomical site produces lipohypertrophy with altered absorption and palpable tissue changes. The rotation discipline addressed in Section 5 is the structural mitigation.

Forgetting site documentation. Users dosing daily or multiple times daily who do not track which sites have been used inevitably default to the most convenient site (typically right abdomen for right-handed injectors) and over-rotate to that quadrant. Written or app-based tracking is the standard practitioner-protocol mitigation.

Re-using a needle across multiple draws or injections. A needle that has passed through a rubber stopper has accumulated micro-coring damage and surface contamination; using the same needle to draw from a vial and then to inject is the practitioner-protocol minimum but represents lower sterility than the two-needle approach (one needle to draw, replace with a fresh needle for injection). The two-needle approach is the gold-standard practice for chronic-injection protocols where infection-risk reduction is the priority.

Storage-driven dose drift. Reconstituted peptide stored beyond the labeled in-use window or stored under inappropriate conditions (room temperature for refrigerated products, repeated freeze-thaw, ambient light for photolabile molecules) degrades at the relevant chemistry's rate. The user dosing on a stable-volume protocol with a partially degraded vial delivers less active peptide than the volume math predicts. The storage and stability reference covers the per-molecule chemistry.

10. Special populations

Children

Pediatric peptide administration is a specialist context outside the scope of adult self-administration. Smaller body mass requires smaller absolute doses; smaller subcutaneous depth (particularly in lean pediatric subjects) requires shorter needles; the dose-conversion math is done by the prescribing clinician with parent or guardian execution. The pediatric peptide use review addresses the broader landscape. The rare pediatric peptide indications (pediatric growth-hormone-deficiency products, trofinetide for Rett syndrome) all carry pediatric-specific administration guidance in the labeled prescribing information.

Elderly

Reduced skin elasticity, thinner subcutaneous fat at some anatomical sites, and increased capillary fragility produce higher rates of bruising and injection-site sequelae in older adults. Vision and fine-motor dexterity changes can affect syringe-reading accuracy. Practitioner mitigations include: shorter needles to ensure subq rather than IM deposition in lean older adults; larger-volume syringes (U-50 over U-30) where the larger graduation spacing improves readability; assisted-administration support where dexterity is limited; clinical follow-up to catch slow-onset injection-site complications.

Obese subjects

The subcutaneous adipose layer is thicker in obese subjects, and the standard 4-to-6 mm subq needle reliably reaches subcutaneous tissue regardless of BMI per the FITTER 2016 consensus. The opposite concern — that the needle is too short — is not supported by the consensus literature for 4 mm needles at any adult BMI. Pinch technique is less necessary, and flat insertion at 90 degrees is the standard approach. The relevant consideration in obese subjects is more often dose calculation than technique per se: peptide dosing scaled by absolute mass rather than per-kilogram produces different per-kilogram exposures across the BMI range, and the prescribing literature handles the dose-scaling question per molecule.

11. What this page is not

A reference dossier, not a practice manual. Not a replacement for prescriber instructions for any specific molecule. Not individualized medical advice. Not an endorsement of any specific gray-market protocol — the protocols cited here are documented as the practitioner-channel convention layer that exists rather than as protocols this site recommends. The FDA package inserts are the authoritative source for administration of the labeled products; the prescribing clinician and the user's personal medical context are load-bearing for any actual technique decision.

The peptide storage and stability technical reference covers pre-injection chemistry; the peptide pharmacokinetics matrix covers post-injection pharmacology; the peptide research glossary defines the manufacturing and chemistry vocabulary; the compounded GLP-1 equivalence myth critic addresses the regulatory frame; and the injection technique doesn't matter critic addresses the over-correction this dossier is the counterweight to. The administration layer is operational rather than theoretical, and the operational discipline is what separates a safe self-administration practice from the error catalog in Section 9.

Sources cited

External primary and regulatory references verified for this dossier:

• Frid, Kreugel, Grassi, Halimi, Hicks, Hirsch, et al., Mayo Clinic Proceedings 2016, 91:1231–1255 — New Insulin Delivery Recommendations (FITTER consensus)
• FDA Alert on Dosing Errors with Compounded Injectable Semaglutide Products, July 29, 2024
• WEGOVY (semaglutide) prescribing information, 2025
• Egrifta WR (tesamorelin) prescribing information, 2025
• Vyleesi (bremelanotide) prescribing information, 2019
• Bacteriostatic Water for Injection USP — Pfizer/Hospira labeling
• Buckley et al., Science Translational Medicine 2018, 10:eaar7047 — SNAC absorption enhancer for oral semaglutide
• Gershanik et al., NEJM 1982, 307:1384–1388 — Gasping syndrome and benzyl alcohol poisoning in neonates
• Belchetz et al., Science 1978, 202:631–633 — Pulsatile GnRH and gonadorelin pulsatile-pump rationale
• Wang et al., Frontiers in Pharmacology 2022, 13:1026182 — BPC-157 pharmacokinetics in rats and dogs
• Imbimbo et al., European Journal of Clinical Pharmacology 1994, 46:421–425 — Hexarelin Phase 1 pharmacokinetics
• Acadia Pharmaceuticals, Daybue (trofinetide) for Rett syndrome approval announcement
• American Diabetes Association — Insulin Administration position statement

In-corpus references cross-linked from this dossier:

• Peptide storage and stability technical reference — diluent chemistry and reconstitution
• Peptide pharmacokinetics matrix — per-molecule half-life and dose-frequency
• Peptide research glossary — manufacturing and chemistry vocabulary
• Peptide manufacturing technical reference — cGMP framework
• Pediatric peptide use review — pediatric administration context
• Injection technique doesn't matter critic — the rebuttal counterpart
• Compounded GLP-1 equivalence myth critic — regulatory frame
• Manchenko et al. 2010 Semax route-dissociation paper
• Vasileva et al. 2020 across Selank/Semax/Noopept routes
• Dalmasso et al. 2008 KPV PepT1 mechanism
• Ehlers et al. 2024 elamipretide ReCLAIM-2 dry AMD
• Sosne 2015 TB-4 dry-eye Phase 2
• Individual peptide pages linked inline throughout the route, special-cases, and per-molecule sections